医药LOF(160219)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
63,542,553.62 |
31,852,714.66 |
-103,157,035.73 |
-162,702,276.64 |
| 利息合计 |
147,005.62 |
72,345.51 |
319,466.31 |
186,009.71 |
| 其中:存款利息收入 |
147,005.62 |
72,345.51 |
319,466.31 |
186,009.71 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-6,536,064.47 |
2,987,654.82 |
-43,043,166.34 |
-24,886,612.67 |
| 其中:股票投资收益 |
-17,595,731.59 |
-3,941,615.56 |
-57,266,329.88 |
-32,907,023.16 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
41,655.66 |
24,486.69 |
125,722.04 |
32,201.78 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
11,018,011.46 |
6,904,783.69 |
14,097,441.50 |
7,988,208.71 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
69,726,149.18 |
28,709,291.37 |
-60,720,790.03 |
-138,079,534.58 |
| 其他收入 |
205,463.29 |
83,422.96 |
287,454.33 |
77,860.90 |
| 费用 |
9,199,449.59 |
4,605,278.40 |
9,836,406.64 |
5,066,096.76 |
| 管理人报酬 |
7,458,938.48 |
3,713,048.13 |
7,855,314.43 |
4,026,592.76 |
| 基金托管费 |
1,491,787.76 |
742,609.68 |
1,571,062.93 |
805,318.56 |
| 销售服务费 |
53,849.00 |
31,043.43 |
59,711.50 |
28,117.34 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
194,874.35 |
118,577.16 |
350,317.78 |
206,068.10 |
| 利润总额 |
54,343,104.03 |
27,247,436.26 |
-112,993,442.37 |
-167,768,373.40 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年